Report of a study into skin sensitivity and into scar diameter after vaccination with BCG in 5,000 new-borns in Cakovec, Yugoslavia.
To compare the skin allergy producing potency of batches of BCG from three different production centers, 5,066 new-borns were vaccinated with one of there batches (one from the Netherlands, one from Yugoslavia and one from Denmark). Six, twelve and twenty-one months after vaccination tuberculin testing was done and the diameter of scars was measured in subgroups. Skin allergy through BCG-vaccination was registered to be highest after 6 months and appeared to wane rapidly afterwards. There was a definite difference in the skin allergy potency between the three vaccines. The difference in scar diameter was less pronounced. In 5,066 vaccinated new-borns 137 (2.7%) enlarged axillar glands were registered. There appeared to be a positive correlation between the mean Mx-induration 6 months after vaccination and the percentage of enlarged glands. No serious complications have been registered so far.
D001500:BCG Vaccine / Q000276:immunology; D002921:Cicatrix / Q000473:pathology; D006801:Humans; D006968:Hypersensitivity, Delayed; D007231:Infant, Newborn; D014376:Tuberculosis / Q000517:prevention & control*; D015022:Yugoslavia
D001500:BCG Vaccine